Lv24
193 积分 2020-11-18 加入
Development of RMC-6236, a potent and orally bioavailable RAS(ON) multi-selective tri-complex inhibitor for the treatment of RAS-addicted cancers by targeting multiple RAS variants
1小时前
已完结
Mechanisms Underlying Plk1 Polo-Box Domain-Mediated Biological Processes and Their Physiological Significance
2天前
已完结
PLK1 inhibition-based combination therapies for cancer management
2天前
已完结
Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma
3天前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
7天前
已完结
The pleiotropic roles of ADAM9 in the biology of solid tumors
10天前
已完结
Targeting uPA/uPAR in prostate cancer
16天前
已完结
The NKG2A immune checkpoint — a new direction in cancer immunotherapy
16天前
已完结
Exploiting Synthetic Lethality in PDAC with Antibody Drug Conjugates and ATR inhibition
21天前
已完结
Exploring the next generation of antibody–drug conjugates
21天前
已完结
皖公网安备34019202002308
